Hepatitis B Treatment: What We Know Now and What Remains to Be Researched

Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, interferons (IFNs) and nucleos(t)ide analogues (NAs), have been approved. These treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosi...

Descripción completa

Detalles Bibliográficos
Autor principal: Suk‐Fong Lok, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312657/
https://www.ncbi.nlm.nih.gov/pubmed/30619990
http://dx.doi.org/10.1002/hep4.1281
_version_ 1783383809990852608
author Suk‐Fong Lok, Anna
author_facet Suk‐Fong Lok, Anna
author_sort Suk‐Fong Lok, Anna
collection PubMed
description Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, interferons (IFNs) and nucleos(t)ide analogues (NAs), have been approved. These treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. However, these treatments do not eliminate the virus, and the risk of HCC remains. This review article summarizes current knowledge about the safety, efficacy, and clinical indications of hepatitis B treatment. It also discusses limitations of existing treatment, gaps in knowledge, and feasibility of a hepatitis B cure.
format Online
Article
Text
id pubmed-6312657
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63126572019-01-07 Hepatitis B Treatment: What We Know Now and What Remains to Be Researched Suk‐Fong Lok, Anna Hepatol Commun Reviews Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, interferons (IFNs) and nucleos(t)ide analogues (NAs), have been approved. These treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. However, these treatments do not eliminate the virus, and the risk of HCC remains. This review article summarizes current knowledge about the safety, efficacy, and clinical indications of hepatitis B treatment. It also discusses limitations of existing treatment, gaps in knowledge, and feasibility of a hepatitis B cure. John Wiley and Sons Inc. 2018-11-15 /pmc/articles/PMC6312657/ /pubmed/30619990 http://dx.doi.org/10.1002/hep4.1281 Text en © 2018 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Suk‐Fong Lok, Anna
Hepatitis B Treatment: What We Know Now and What Remains to Be Researched
title Hepatitis B Treatment: What We Know Now and What Remains to Be Researched
title_full Hepatitis B Treatment: What We Know Now and What Remains to Be Researched
title_fullStr Hepatitis B Treatment: What We Know Now and What Remains to Be Researched
title_full_unstemmed Hepatitis B Treatment: What We Know Now and What Remains to Be Researched
title_short Hepatitis B Treatment: What We Know Now and What Remains to Be Researched
title_sort hepatitis b treatment: what we know now and what remains to be researched
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312657/
https://www.ncbi.nlm.nih.gov/pubmed/30619990
http://dx.doi.org/10.1002/hep4.1281
work_keys_str_mv AT sukfonglokanna hepatitisbtreatmentwhatweknownowandwhatremainstoberesearched

Ejemplares similares